Clinical trials: Neoplasms, Germ Cell and Embryonal
Malignant Glioma, Recurrent Glioblastoma
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas.
- Trial name
- NCT01266031
- Testing
- vorinostat, bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
GBM, Glioblastoma Multiforme (GBM)
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
The goal of this clinical trial is to evaluate the safety and feasibility of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) in adults with glioblastoma (GBM)…
- Conditions
- GBM, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Glioma
- Trial name
- NCT07179328
- Testing
- Focused Ultrasound Next Generation Dome Helmet, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Melanoma
Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)
Sentinel lymph node biopsy (SLNB) is considered as standard diagnostic procedure in melanoma patients carrying a reasonable risk for metastases.
- Trial name
- DeCOG-SLT (NCT02434107)
- Testing
- Completion Lymphadenectomy, Clinical Monitoring (Palpation and node ultrasound)
- Where
- 41 sites in Germany
- Volunteers
- 483 people
- Sponsor
- University Hospital Tuebingen
Melanoma
Phase IIB TL + YCWP + DC in Melanoma
The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants.
- Trial name
- NCT02301611
- Testing
- TLPLDC
- Where
- 18 sites in United States
- Volunteers
- 187 people
- Sponsor
- Elios Therapeutics, LLC
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Vestibular Schwannoma, Inner Ear Disease
Vestibular Precision: Physiology & Pathophysiology
This project will investigate the role of noise in the vestibular system, and in particular its effects on the variability (precision) of vestibular-mediated behaviors.
- Conditions
- Vestibular Schwannoma, Inner Ear Disease, Dizziness, Neurofibromatosis 2
- Trial name
- NCT04890132
- Testing
- VOR precision training
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Brain and Central Nervous System Tumors
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00387400
- Testing
- everolimus, temozolomide, microarray analysis
- Where
- 9 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002944
- Testing
- carboplatin, lomustine, procarbazine hydrochloride
- Where
- 204 sites in United States, Australia and 4 more
- Volunteers
- 428 people
- Sponsor
- Children's Oncology Group
Metastatic Neuroblastoma
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma
This study aims to show that 3-dimensional PET/CT imaging with a new novel PET tracer (called [124I]mIBG) can detect as many or more sites of neuroblastoma (a type of childhood cancer) compared to the recommended 1-dimensional…
- Trial name
- NCT02043899
- Testing
- [124I]meta-Iodobenzylguanidine
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Cancer Research UK
Glioma
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
Gliomas represent the most frequent primary brain tumor, with 2,500 to 3,000 new cases per year in France. Their diagnosis, although highly complex, is essential for determining patient management.
- Trial name
- circTeloDIAG (NCT04931732)
- Testing
- ctDNA analysis
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Recurrent Melanoma, Stage IV Melanoma
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a…
- Trial name
- NCT02263898
- Testing
- Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Melanoma
Radiation and Combination Immunotherapy for Melanoma
This is a Phase 2 study designed to evaluate the combination of checkpoint blockade and aldesleukin (IL-2) therapy after a course of standard of care palliative radiation in the management of unresectable metastatic melanoma.
- Trial name
- NCT03850691
- Testing
- Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neuroblastoma
Haploidentical Stem Cell Transplantation in Neuroblastoma
Children with primary resistant or relapsed neuroblastoma who do not achieve remission with conventional chemotherapy have extremely dismal prognosis.
- Trial name
- NCT00790413
- Testing
- iodine I 131 metaiodobenzylguanidine, Fludarabine, Thiotepa
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Lund University Hospital
Melanoma Stage Iv, Metastatic Melanoma
Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet
This research will study the effect of Mediterranean diet intervention in patients undergoing immunotherapy treatment for metastatic melanoma and its relationship with gut microbiome and quality of life.
- Trial name
- MINI-MD (NCT06236360)
- Testing
- Mediterranean Diet Intervention
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- University Hospital Rijeka
Recurrent High Grade Glioma
PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas
This trial is an open-label, single-arm, phase 0/1 study of high-grade glioma that aims to evaluate the feasibility, preliminary efficacy and safety of the precision treatment strategy.
- Trial name
- NCT05473923
- Testing
- Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Gliomas
Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas
In this study, we evaluate the role of diffusion kurtosis imaging (DKI) and MR spectroscopy (MRS), two advanced imaging techniques in magnetic resonance (MR) in grading and detection of microscopic infiltrating tumour in gliomas.
- Trial name
- NCT01225003
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Brain and Central Nervous System Tumors
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as gossypol and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390403
- Testing
- R-(-)-gossypol acetic acid, temozolomide, gene expression analysis
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
This is a phase one trial to determine if genetically engineered lymphocytes can be safely delivered to patients with metastatic melanoma.
- Trial name
- NCT01586403
- Testing
- Dose 1, Dose 2, Dose 3
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Loyola University
Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas.
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype
- Trial name
- NCT04623931
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Unresected Stage IIIB to IVM1c Melanoma
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
The study is a phase 3b, multicenter, open-label, single-arm study designed to provide expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma.
- Trial name
- NCT02297529
- Testing
- Talimogene Laherparepvec
- Where
- 3 sites in Switzerland
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.